Technology
Health
Biotechnology

CEL-SCI

$3.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (1.32%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CEL-SCI and other stocks, options, ETFs, and crypto commission-free!

About

Cel-Sci Corporation, also called CEL-SCI, is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Read More Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Employees
Headquarters
Vienna, Virginia
Founded
1983
Market Cap
84.09M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
567.22K
High Today
$3.14
Low Today
$2.97
Open Price
$3.13
Volume
116.33K
52 Week High
$4.44
52 Week Low
$0.8165

Collections

Technology
Health
Biotechnology
Cancer Prevention
US
North America

Earnings

-$0.70
-$0.46
-$0.22
$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected May 15, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.